Lantheus Holdings Inc. (NASDAQ:LNTH) traded down 1.1% during mid-day trading on Friday . The stock traded as low as $9.35 and last traded at $9.40, with a volume of 286,896 shares traded. The stock had previously closed at $9.50.

Several equities research analysts recently issued reports on the stock. Zacks Investment Research cut shares of Lantheus Holdings from a “buy” rating to a “hold” rating in a research report on Thursday, May 12th. Jefferies Group restated a “buy” rating on shares of Lantheus Holdings in a research report on Friday, August 5th. Finally, Credit Suisse Group AG set a $4.00 price objective on shares of Lantheus Holdings and gave the stock a “hold” rating in a research report on Friday, August 5th. Three equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. Lantheus Holdings presently has a consensus rating of “Buy” and a consensus target price of $6.60.

The firm’s 50 day moving average price is $6.18 and its 200 day moving average price is $3.38. The company has a market capitalization of $285.64 million and a price-to-earnings ratio of 10.61.

Lantheus Holdings (NASDAQ:LNTH) last posted its earnings results on Thursday, August 4th. The company reported $0.24 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.06 by $0.18. The business had revenue of $78 million for the quarter, compared to analyst estimates of $72.66 million. On average, equities analysts anticipate that Lantheus Holdings Inc. will post $0.54 EPS for the current year.

Lantheus Holdings, Inc develops, manufactures and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. The Company’s portfolio of approximately 10 commercial products is spread across a range of imaging modalities.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.